Novel dosage forms and regimens for sevelamer-based phosphate binders.
Sevelamer, a nonabsorbed, calcium- and metal-free dietary phosphate binder, consists of a polyallylamine polymer backbone with a cationic charge that shows a high capacity for binding anionically charged compounds such as phosphate. The currently licensed form of sevelamer, Renagel, exists as sevelamer hydrochloride, which disassociates in the acidic environment of the stomach and early gastrointestinal tract, exchanging the chloride ions attached to the polymer backbone for phosphate ions. The resulting absorption of these chloride ions has been reported to be accompanied by a reduction in serum levels of bicarbonate in some patients. To minimize the possibility of this effect, a new salt form of sevelamer has been developed in which carbonate replaces the chloride counter ion, thereby providing a source of buffer. The majority of phosphate binders exist only in tablet form and are dosed three times per day with meals. Genzyme has developed sevelamer carbonate in tablet form and also as a powder formulation that can be taken after mixing with water. This allows for an alternate and potentially more palatable way of dosing. Preliminary data exist suggesting that once daily dosing with sevelamer hydrochloride tablets provides similar phosphate control to three times daily dosing. By providing novel dosage forms and regimens for sevelamer-based phosphate binders, Genzyme will be providing patients and health care providers additional choices and flexibility in controlling phosphorus levels in chronic kidney disease. This should translate to increased compliance and improved rates of phosphate control.
Duggal
Ajay
A
Genzyme Europe Research, Cambridge, England. ajay.duggal@genzyme.com
Hanus
Martin
M
Zhorov
Eugene
E
Dagher
Rafif
R
Plone
Melissa A
MA
Goldberg
Jeffrey
J
Burke
Steven K
SK
D000818:Animals; D001639:Bicarbonates / Q000097:blood; D002712:Chlorides / Q000737:chemistry; D004285:Dogs; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D007700:Kinetics; D010349:Patient Compliance; D010710:Phosphates / Q000097:blood* / Q000737:chemistry; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D006435:Renal Dialysis; D000069603:Sevelamer
D001639:Bicarbonates; D002712:Chlorides; D010710:Phosphates; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer